Affordable Access

deepdyve-link
Publisher Website

Medical resource use and cost of different first-line treatments for metastatic colorectal cancer in Brazil.

Authors
  • Caponero, Ricardo
  • Ribeiro, Ronaldo de Albuquerque
  • Santos, Eduardo
  • Cirrincione, Alessandro
  • Saggia, Mario
Type
Published Article
Journal
Journal of Medical Economics
Publisher
Informa UK Limited
Publication Date
Jan 01, 2008
Volume
11
Issue
2
Pages
311–325
Identifiers
DOI: 10.3111/13696990802160817
PMID: 19450088
Source
Medline
License
Unknown

Abstract

The panel concluded that regimens containing capecitabine, especially capecitabine plus oxaliplatin (XELOX) are less expensive than those containing 5-FU/leucovorin. Given the comparable efficacy and good tolerability of the XELOX regimen, it may be an attractive choice for the first-line treatment of Brazilian patients with mCRC.

Report this publication

Statistics

Seen <100 times